US-based Diffusion Pharmaceuticals has started dosing patients in the Phase III INTACT clinical trial of its product candidate trans sodium crocetinate (TSC) for the treatment of newly diagnosed inoperable glioblastoma multiforme (GBM).
TSC is being developed to counteract tumour hypoxia to make treatment-resistant cancer cells more susceptible to the standard radiation therapy (RT) and chemotherapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label, randomised, controlled Phase III trial will compare the overall survival of patients receiving a combination of TSC with standard of care (SoC) RT and those having chemotherapy or SOC alone.
Using temozolomide as the SoC drug, the trial will be conducted in approximately 264 subjects at up to 100 sites in the US and Europe.
The INTACT trial will evaluate safety, tolerability and pharmacokinetics (PK) of TSC at doses higher than 0.25mg/kg with temozolomide during combination therapy.
A baseline assessment will be carried out at ten weeks to establish progression-free and survival overall response rate, while ruling out pseudo-progression.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDiffusion Pharmaceuticals CEO David Kalergis said: “We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago.
“We believe that this Phase III study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”
In a prior Phase II trial, inoperable GBM patient subgroup is reported to have demonstrated increased survival with the addition of TSC to the treatment regimen, when compared with historical controls.
